Stanford to tighten conflicts rules again; Biovail founder sells all remaining shares;

 @FiercePharma: AstraZeneca wins bellwether Seroquel case. Article | Follow @FiercePharma

> The Stanford University School of Medicine plans to introduce rules that would prohibit its adjunct faculty from giving paid speeches drafted by the makers of drugs or medical devices. Report

> Biovail founder Eugene Melnyk said he has sold all his shares in the company, ending a long and tempestuous relationship with the Canadian drugmaker. Report

> Japan's Astellas Pharma, which is pursuing a $3.5 billion hostile takeover of OSI Pharmaceuticals, has replaced two of the nominees it plans to put up for election to the OSI board. Release

> Japan's Takeda Pharmaceutical used a misleading promotion for its insomnia drug Rozerem, FDA says in a letter released Friday. Report

> Swiss drugmaker Roche is looking to broaden the use of its cancer drug MabThera in non-Hodgkin's lymphoma in Europe. Report

> Pfizer said it expects a positive decision by the end of May on the inclusion of new pediatric data on labelling in Europe for its cholesterol drug Lipitor. Report

> A two-in-one prostate drug from GlaxoSmithKline won approval in Switzerland, its first European market, the British-based drugmaker reports. Release

> India's Lupin said a subsidiary has received tentative FDA approval to sell its version of the Sepracor sleep drug Lunesta. Report

Biotech News

 @FierceBiotech: Roll Call's list of highest paid trade association lobbyists, with PhRMA/BIO accounting for 8 of top 20. Article | Follow @FierceBiotech 

 @JohnCFierce:  RT @adamfeuerstein: $CTIC Voting Question: Does this single, incomplete trial of pixantrone adequate to support approval? Yes: 0, No: 9. | Follow @JohnCFierce

> In what amounts to a make-or-break day for Seattle-based Cell Therapeutics, the company took its case for the cancer drug pixantrone to an expert panel convened by the FDA this morning. Article

> Nodality gains backing from Pfizer Ventures in $15.5 million round. Report 

> Agennix raises $13 million for late-stage cancer trial. Story

> Investigators shape a workable public/private development model. Item

> Biotech wins 12-year haven with passage of reform bill. Report

Biotech IT News

> The clinical trial of an iPhone application aims to prove its efficacy as treatment for depression. Article

> Adaptive trial to aid cancer drug choice. Story

> Trial aids boost cardiac safety. Report

And Finally... Johns Hopkins scientists found that a safe and inexpensive antibiotic in use since the 1970s for treating acne may be an effective tool against HIV. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.